Publications by authors named "Pernille D Ovesen"
The Copenhagen Hospital Biobank-chronic inflammatory disease-inflammatory bowel disease (CHB-CID: IBD) cohort contributes to genetic research in inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Of the 327,084 enrolled and genotyped individuals in the cohort, 10,626 have been diagnosed with IBD as of May 2023. The CHB-CID: IBD cohort includes both patients without IBD and healthy blood donors as control groups.
View Article and Find Full Text PDFBackground And Aims: Crohn's disease (CD) is characterized by progressive intestinal transmural damage, including fibrosis and strictures, which impair quality of life and require surgical intervention. No anti-stricture therapies are available, and no accurate biomarkers have been validated allowing prediction of strictures. Collagen fragments synthesis and remodeling show potential as markers of transmural disease activity.
View Article and Find Full Text PDFBackground And Aims: Up to 30% of patients with acute severe ulcerative colitis (ASUC) will require urgent colectomy despite initiation of intravenous corticosteroids and rescue therapies. Janus kinase inhibitors, such as tofacitinib, have emerged as an effective agent for ASUC; however, there are currently limited data evaluating the risk of postoperative complications among patients who received tofacitinib treatment for an episode of ASUC compared with infliximab.
Methods: We conducted a multicenter, retrospective, case-control study of patients hospitalized with ASUC who underwent colectomy, comparing patients treated with tofacitinib prior to colectomy with infliximab-treated controls.
Background And Aims: Existing findings on outcomes of anti-tumor-necrosis-factor (TNF) therapy in patients with inflammatory bowel diseases (IBD) are largely based on retrospective studies. We aimed to investigate real-world outcomes of anti-TNF therapy and predictors thereof in a prospective IBD cohort.
Methods: In a Danish multicenter cohort of adult bio-naïve patients with IBD treated with anti-TNF, we assessed clinical response and remission to induction therapy using clinical disease activity scoring indices at Week 14.
Background: Biological treatment failure is common in patients with ulcerative colitis (UC), but the predictive value of baseline histological activity is unknown.
Aims: We aimed to investigate the associations between baseline histological activity and outcomes after biological treatment in patients with UC.
Methods: Adult biological-naïve patients with UC (n = 150) were followed prospectively during biological treatment.
Article Synopsis
- Current methods for assessing inflammatory bowel disease (IBD) are often invasive or inaccurate, highlighting the need for non-invasive biomarkers, particularly blood extracellular matrix (ECM) markers.
- A systematic review identified 31 ECM markers related to IBD, with Collagen III being the most studied; markers C3M and PRO-C3 are linked to disease activity, while C5M and PRO-C5 showed high diagnostic accuracy for IBD.
- Despite promising connections between ECM markers and IBD, the studies lacked standardized endpoints and histological assessment, suggesting that further rigorous research is needed to validate these biomarkers for clinical use.*
Background And Aims: Despite advances in the medical treatment of Crohn's disease [CD], many patients will still need bowel resections and face the subsequent risk of recurrence and re-resection. We describe contemporary re-resection rates and identify disease-modifying factors and risk factors for re-resection.
Methods: We conducted a retrospective, population-based, individual patient-level data cohort study covering 47.
Article Synopsis
- A study was conducted to evaluate how prednisolone affects clinical outcomes and safety in ulcerative colitis patients treated with infliximab, with a focus on corticosteroid-free clinical remission (CFCR).
- Among the 147 patients reviewed, there was no overall association between prednisolone use and CFCR at weeks 14 or 52, but standard tapering of prednisolone showed better results compared to faster tapering regimens.
- Despite no impact on infliximab levels, higher infection rates were noted in patients taking prednisolone, especially in those with greater disease severity, suggesting that corticosteroid therapy may benefit certain patients.